Pfizer's innovative drug is approved in China to treat recurrent or refractory acute leukemia

Pfizer today announced that the China National Drug Administration has approved Bebossa (oghaltizumab for injection) for adult patients with recurrent or refractory precursor B-cell acute lymphoblastic leukemia (ALL), the world's first antibody-drug conjugate (ADC) approved for the treatment of R/R B-ALL.

Leukemia is a common tumor of the hematolymphatic system, and more than 80,000 new leukemia patients will be added to China in 2020. Acute lymphoblastic leukemia (ALL), one of the four main types of leukemia, is a malignant neoplastic disease in which B or T cells originate in lymphocytes and abnormally proliferate in the bone marrow. Abnormally proliferative blast cells can aggregate in the bone marrow and inhibit normal hematopoietic function, and can also invade tissues outside the bone marrow. At present, the treatment of ALL patients in China is mainly chemotherapy, of which 40%-50% of adult patients will eventually experience recurrence, and the total survival rate of patients in five years is less than 10%. Under traditional standard chemotherapy regimens, patients with R/R ALL have difficulty achieving complete remission (CR) and achieving long-term survival.

ADC drugs change the status quo of treatment in adult patients with R/R ALL. As one of the current hot drugs in tumor immunotherapy, with its unique tumor specificity and efficacy, ADC drugs can not only expand the tumor treatment time window, but also minimize chemotherapy-related adverse reactions injection of Oga igalizumab as one of the representative drugs of ADC, can improve the CR rate of R/R B-ALL treatment, so that more patients have the opportunity to carry out hematopoietic stem cell transplantation, and then achieve the purpose of long-term survival, which is expected to help the establishment of new treatment standards, which is R/R A milestone in the field of B-ALL treatment.

Xinmin Evening News reporter Zuo Yan